Episode
Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.
- Podcast
- Business Of Biotech
- Published
- Nov 24, 2025
- Duration seconds
- 3521
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/biotech-collaboration-strategy-with-igi-s-cyril-konto-m-d/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/biotech-collaboration-strategy-with-igi-s-cyril-konto-m-d.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration. Cyril also discusses IGI's focus on developing innovative therapies for em...